Farxiga

DRUG2 trials

Sponsors

AstraZeneca, Baylor Research Institute

Conditions

Chronic Kidney DiseaseType 2 DiabetesType II Diabetes

Phase 4

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

CompletedNCT02429258

AstraZenecaType II Diabetes

Start: 2015-05-31End: 2015-10-31Updated: 2017-06-14

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Not yet recruitingNCT07547878

Baylor Research InstituteChronic Kidney Disease, Type 2 Diabetes

Start: 2026-04-30End: 2029-03-31Target: 64Updated: 2026-05-08